Affimed turns its back on T-cell recruitment
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
Macrogenics’ safety scare could be contagious
It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.
